ClinicalTrials.gg
RecruitingNCT07506356SAGUSEUpdated Apr 1, 2026

Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors

An observational study in Diabete Type 2, Regurgitation and Pulmonary Aspiration During Anaesthetic Induction, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by University Hospital, Geneva · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
38
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland — 13 open to participants now, 18 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Switzerland.

Planned enrollment
20th of 21
38 · median 450
Started
2026
with 3 others
Observational
21 of 112
4 open now
Primary completion
2026-12
later than 5 of 17 live
Registered
110th of 112
by date

Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, this one is the 20th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, reaches primary completion later than 5 of the 17 other live ones, and was the 110th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, or all of them as a file.
02

Study summary

Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach.

This is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days.

To recruit the necessary number of participants, approximately 1.5 years will be needed.

This project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project.

The project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and/or cereals and/or proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam.

At 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.

03

Conditions studied

  • Diabete Type 2
  • Regurgitation
  • Pulmonary Aspiration During Anaesthetic Induction

Keywords

  • GLP-1 agonists
  • GLP-1 analog
  • Diabetes
  • Gastric ultrasound
  • Anesthesia
  • GUS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diabetic patients treated by GLP-1 analog

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female/ Male of 18 years old or more
  • With Type 2 Diabetes
  • Treated with GLP 1 analog for more than 3 months
  • Signed consent
  • ASA between I and IV

Exclusion criteria

Exclusion Criteria:

  • Insuline treatment
  • Gastro intestinal motility disorders
  • Past gastric surgery
  • Hiatal hernia
  • Recent trauma
  • Inability to be lay down for the exam
  • Inability to follow the instructions for the exam (language, dementia)
  • > 40
  • Inability to stop smoking 12h before the measures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
38 participants (estimated)
Target follow-up
7 Days
Patient registry
Yes

Groups and cohorts

  • Diabetic patients under GLP-1 receptors agonists
06

What researchers measure

Primary outcomes

  1. A safe gastric volume for anesthesia in diabetic patients treated with GLP-1 analog after a 6 hours fasting period 7 day after the last injection.

    Our primary objective is to show that after a fasting period of 6 hours, seven days after the last injection of GLP-1, gastric volume of diabetic patients is safe for anaesthesia. Our hypothesis is that seven days after the last injection of GLP-1, and after a 6h fasting period, the mean gastric volume of treated patients will be lower than 1.5 ml/kg, corresponding to the most accepted volume threshold of an at risk (full) stomach

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 8 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2026
First posted
Apr 1, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07506356
Responsible party
Dr Rey-Millet Quentin (Dr, Principal Investigator, University Hospital, Geneva) — Principal investigator
First posted
Apr 1, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion